DIFFERENTIAL-EFFECTS OF DIETARY CALCIUM AUGMENTATION AND HORMONE REPLACEMENT THERAPY ON BONE TURNOVER AND SERUM LEVELS OF CALCITROPHIC HORMONES

The mechanism of action of retardation of postmenopausal bone loss may be different for dietary calcium augmentation and hormonal replacemen t therapy (HRT). We performed a three-arm, placebo-controlled, randomi zed clinical trial comparing an intake of calcium of 1700 mg with: (1) calcium augmentation with HRT and (2) placebo. One hundred and eighte en women entered the study; 17 patients dropped out of the study. The vast majority of women were less than 2 years postmenopause. Bone mine ral density declined significantly in the placebo group. The previousl y reported rates of change in the HRT group were significantly positiv e for total body calcium and the trochanter and not significantly diff erent from zero for the others. The rate of change in the calcium augm entation group was intermediate between that in the two other groups, and achieved statistical significance compared with placebo for the to tal body calcium measurement and for the neck of the femur. Measuremen ts were made prior to treatment and at the end of the study (2.9 years +/- 1.1 SD) for parameters of bone turnover and the calcitrophic horm ones, to examine whether the mechanism of action was different for cal cium augmentation versus hormonal therapy. There were no changes in th e placebo group. The calcium augmentation group had a significant incr ease in 24-h urinary calcium and declining values for urinary collagen cross-links (pyridinium and deoxypyridinium): urinary hydroxyproline and calcitriol. The group treated with HRT and dietary calcium augment ation also had an increase in urinary calcium and a decline in collage n cross-links and urinary hydroxyproline and skeletal alkaline phospha tase; serum calcitriol did not change. The HRT group also displayed a drop in serum osteocalcin, and an increase in nephrogenous cAMP. Serum parathyroid hormone remained unchanged in all groups. Dietary calcium augmentation retards postmenopausal bone loss by decreasing resorptio n. The addition of HRT results in a more marked decline in bone resorp tion parameters and a suppression of parameters of bone formation. Whe reas calcium augmentation suppressed calcitriol levels, the addition o f HRT resulted in maintenance of calcitriol levels, possibly through e nhancement of the renal effects of parathyroid hormone, although other mechanisms are possible.